Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes
Response to Ryan, Imes, and Wallace
- Keiji Yoshioka, MD1,
- Toshihide Yoshida, MD2 and
- Toshikazu Yoshikawa, MD3
- 1Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
- 2Department of Diabetes and Metabolism, Kyoto City Hospital, Kyoto, Japan
- 3Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
- Address correspondence to Keiji Yoshioka, MD, Matsushita Memorial Hospital, Department of Diabetes and Endocrinology, 5-55, Sotojima-cho, Moriguchi, Osaka, 570-8540 Japan. E-mail: yoshik{at}mue.biglobe.ne.jp
The recent report by Ryan et al. (1) demonstrated that in newly diagnosed type 2 diabetes, a short course of intensive insulin therapy successfully laid a foundation for long-term good glycemic control and suggested that the only predictors that could be maintained on diet alone in the long term were those concerned with the ease with which glycemic control could be achieved. We agree with their strategy of short-term intensive insulin therapy to restore β-cell insulin secretion and/or insulin action that is impaired by glucose …
